0 Item
My accountOur History
tebu-bio past & present
This year, we've attended a number of meetings, presenting results of work performed in our labs. Beginning in January, we presented a poster at the ESACT 2018 meeting in the UK on the topic "Development of advanced 3D culture models to evaluate cellular responses". In April, we attended the AACR meeting in Chicago, presenting a poster entitled "Time-lapse analysis of drug response and invasive capacity using patient-derived CRC microfluidic 3D cancer models under oxygen controlled conditions". Another poster was presented at the DECHEMA 3D Cell culture meeting, on the topic "Advanced physiologically-relevant 3D models for pre-clinical screening". These posters show different aspects of our CellPhy offer, for physiologically relevant conditions.
In May, Isabelle Topin presented a poster "More and Better - Innovative tips and tricks for production and purification of unstable proteins" at the SBCN2018 meeting in Bordeaux, based on her experience as Project Manager of the protein production and purification platform at tebu-bio's laboratories.
In November, Joost Boex (Key Account Manager - tebu-bio Netherlands) attended the Dutch Biophysics meeting, where he presented a poster on "SiR probes - a simple way to decipher complex 3D cell culture models" demonstrating the high efficiency of the SiR probes for Live Cell Imaging.
We are pleased to launch a new service for 3D cell culture spheroid production, recreating the 3D environment seen in the body, thus permitting complex in vitro cell / tissue interactions thus mimicking in vivo environments.
tebu-bio again this year presented a poster at the AACR meeting in Washington, DC (USA). Nadia Normand Ph.D, Business Development Manager at tebu-bio, presented our abstract produced in collaboration with the CNRS (France), Anaxomics (Spain) and the Institute of Immunology and Experimental Therapy (Poland) :
"miRNome analyses reveal that activity of CAF expressed podoplanin in the tumour microenvironment is modulated by exosome miRNAs involved in PTEN/PI3K/AKT/mTOR signalling"
tebu-bio's CIR accreditation is again renewed for a further three years (2017, 2018 & 2019), enabling private French companies to benefit from tax refunds on their expenses for R&D performed by tebu-bio's own European laboratories based near Paris. We initially obtained this accreditation in 2008, which has subsequently been renewed each time.
Nadia Normand, R&D manager at tebu-bio's laboratories, was pleased to present two posters at the AACR meeting in Philadelphia in April:- Comparison of different highly sensitive miRNA array platforms for the investigation of circulating cell-free microRNAs in blood
- Cytokine profiling of drug-disrupted tumor cell/fibroblast crosstalk provides insights to understand the protective role of the stroma in collaboration with the Institut Català d'Oncologia.
As a European-based services provider in genomics, proteomics and cell-based assays, tebu-bio enlarges their service portfolio by offering Toray's 3D-Gene® microRNA and mRNA profiling technology to European researchers (see press release).
tebu-bio is pleased to announce their distribution agreement with Stemgent-Asterand, under which tebu-bio becomes their exclusive European distributor as from July 15, 2014.tebu-bio's CIR accreditation is again renewed for a further three years (2014, 2015 & 2016), enabling private French companies to benefit from tax refunds on their expenses for R&D performed by tebu-bio's own European laboratories based near Paris. We initially obtained this accreditation in 2008, later renewed for the first time in 2011.
tebu-bio launches a series of new e-Newsletters and a blog named "Being bio-reactive", aimed at informing and sharing news in Life Sciences and Biotechnologies.
tebu-bio is a partner of the Glycoskin 1 project, certified by the Cosmetic Valley competitive cluster, which has been selected among the call for proposals (AAP) of the FUI 16. tebu-bio brings to the project their expertise in the screening of molecules in cellular models and in multiplex studies to this project.tebu-bio and tebu-bio Laboratories merge to form a single company, to more efficiently provide reagents & services to researchers across Europe.
.png){kind=logo}
tebu-bio has been designated one of the winners the PM'up award in the Health/Life Sciences sector, which is attributed by the "Region Ile de France" (regional government).
tebu-bio's broad and varied Antibody offer is further enhanced with guaranteed antibodies validated for popular applications. We proudly present our new antibody mascot! Among the new brands: Quansys Biosciences, Sunred Biological Technology, EnoGene Biotech, Assay Biotechnology, MUbio, Biosensis, Osenses, Full Moon Biosystems...
tebu-bio Laboratories receive official renewal of their CIR (Crédit d'Impôt sur la Recherche) accreditation.
tebu-bio APS is opened in Denmark, covering all Nordic territories.
A new unified name is chosen for the group, tebu-bio. SPB is renamed to tebu-bio laboratories.
A shadow is added to the logo.
Premises at Le Perray are extended to include larger offices for technical sales staff, IT, accounting…
The whole of the original building is dedicated to a new Logistics department.
Based in Paris, the new company promotes and sells products manufactured by the Dutch plant.
